A sequenced-strategy for improving outcomes in patients with knee osteoarthritis pain

改善膝骨关节炎疼痛患者预后的序贯策略

基本信息

  • 批准号:
    10700013
  • 负责人:
  • 金额:
    $ 116.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-25 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Knee osteoarthritis (KOA) is one of the leading causes of chronic pain and disability worldwide, affecting over 30% of older adults and represents a major global health and economic burden to individuals and society. The rates of KOA have more than doubled in the past 70 years and continue to grow sharply, given increases in life expectancy and population BMI. Surgery is often employed to treat KOA, but it associated with a high rate of persistent pain, and is not a permanent solution. Numerous nonsurgical therapies have been advocated to treat pain in patients with KOA. However, stand-alone conservative treatments including non-opioid medications and joint injections provide only limited pain relief and functional improvement in a subset of knee OA sufferers. This has led to a high rate of opioid use in this population. The overarching goal of this proposal is to conduct a sequential parallel group randomized controlled trial (RCT) to rigorously evaluate the comparative-effectiveness of conservative behavioral and non-opioid pharmacological treatments (Phase I) and, among non-responders, the benefits of nonsurgical procedural interventions (Phase II) in three inter- related Aims. Aim 1 will evaluate the effectiveness of individual and combined online cognitive behavioral therapy (PainTRAINER) and pharmacologic treatment (duloxetine) in improving pain and function for KOA patients compared to standard of care. Aim 2 will determine if genicular nerve radiofrequency ablation (RFA) or intra-articular injection of hyaluronic acid and steroid are more effective in improving outcomes than local anesthetic nerve block or SOC and help establish the role of these interventional treatments in the overall management of pain in KOA patients. Patients that have failed Phase I treatment will be provided with an opioid for severe pain management, if appropriate, allowing us to examine the opioid-sparing effects of these procedures in a subset of participants. Aim 3 will test whether clinical and psychosocial phenotypes predict short- and long-term treatment response. Our study involves comprehensive and innovative approaches that have never before been employed in this context, including: a multidisciplinary cadre of investigators conducting the largest randomized trial to date evaluating behavioral, pharmacotherapy and nonsurgical procedural interventions for KOA; a stepped-care, factorial design model that allows for more than two dozen pair-wise treatment comparisons; phenotyping to identify responders and improve selection for each therapy (i.e. precision medicine), which is expected to refine outcomes and reduce unnecessary interventions. The results, which will follow pragmatic principles in order to maximize the information provided to stakeholders, will examine not only the effectiveness of each tested intervention but also provide meaningful information regarding effectiveness across key subgroups of patients. The knowledge gained will contribute to the development of translatable therapeutic strategies for the treatment of patients with KOA pain that will lead to opioid sparing effects.
项目摘要/摘要 膝骨性关节炎(KOA)是全世界慢性疼痛和残疾的主要原因之一,影响超过 30%的老年人,对个人和社会来说是一个重大的全球健康和经济负担。这个 在过去的70年里,膝关节骨质疏松症的发生率增加了一倍多,而且由于生活水平的提高,这种比率还在继续急剧增长 预期和人口BMI。手术通常被用来治疗膝关节骨性关节炎,但它与高比率的 持续的疼痛,并不是治标不治本。许多非手术疗法被提倡用来 治疗膝关节骨性关节炎患者的疼痛。然而,包括非阿片类药物在内的独立保守治疗 药物和关节注射只能有限地缓解膝关节的疼痛和改善其功能 骨性关节炎患者。这导致了这一人群中阿片类药物的高使用率。这项提案的首要目标是 是进行序贯平行分组随机对照试验(RCT),以严格评价 保守行为疗法和非阿片类药物疗法的疗效比较(第一阶段) 在无反应者中,非手术程序干预(第二阶段)在三个中间阶段的好处 相关目标。目标1将评估个体和组合在线认知行为的有效性 治疗(Paintriner)和药物治疗(度洛西汀)改善膝关节骨性关节炎的疼痛和功能 将患者与标准护理进行比较。目标2将确定膝神经射频消融术(RFA) 关节内注射透明质酸和类固醇比局部注射更有效 麻醉神经阻滞或SOC,并有助于确定这些介入治疗在总体上的作用 膝关节骨性关节炎患者的疼痛管理。第一阶段治疗失败的患者将获得 用于剧烈疼痛管理的阿片类药物,如果合适,允许我们检查这些药物的阿片类药物的节制效果 参与者子集中的程序。目标3将测试临床和心理社会表型是否能预测 短期和长期治疗反应。我们的研究涉及全面和创新的方法, 以前从未在这种情况下受雇,包括:一支多学科调查队伍 进行迄今为止最大规模的随机试验,评估行为、药物治疗和非手术治疗 KOA的程序性干预;一种阶梯式护理析因设计模型,允许超过24个 配对治疗比较;表型分型以确定应答者并改进每种治疗的选择 (即精准医学),预计将改进结果并减少不必要的干预。这个 结果将遵循务实原则,以最大限度地向利益攸关方提供信息,将 不仅要检查每个经过测试的干预措施的有效性,还要提供有意义的信息 关于关键患者亚组的有效性。所获得的知识将有助于 开发可翻译的治疗策略来治疗膝关节骨性关节炎患者,这将导致 阿片类药物的节制作用。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Reflections on Innovative Interventional Pain-Relieving Procedures: Lessons Learned from Previous Mistakes.
对创新介入止痛手术的反思:从以前的错误中吸取的教训。
  • DOI:
    10.1093/pm/pnz380
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Zhao,Zirong;Larkin,ThomasM;Cohen,StevenP
  • 通讯作者:
    Cohen,StevenP
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Claudia Michelle Campbell其他文献

Claudia Michelle Campbell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Claudia Michelle Campbell', 18)}}的其他基金

Central Sensitization and Sleep Disturbance as Predictors of Treatment Outcomes in Patients with Knee Osteoarthritis
中枢敏化和睡眠障碍作为膝骨关节炎患者治疗结果的预测因素
  • 批准号:
    10456895
  • 财政年份:
    2021
  • 资助金额:
    $ 116.41万
  • 项目类别:
Central Sensitization and Sleep Disturbance as Predictors of Treatment Outcomes in Patients with Knee Osteoarthritis
中枢敏化和睡眠障碍作为膝骨关节炎患者治疗结果的预测因子
  • 批准号:
    10663903
  • 财政年份:
    2021
  • 资助金额:
    $ 116.41万
  • 项目类别:
Central Sensitization and Sleep Disturbance as Predictors of Treatment Outcomes in Patients with Knee Osteoarthritis
中枢敏化和睡眠障碍作为膝骨关节炎患者治疗结果的预测因素
  • 批准号:
    10306938
  • 财政年份:
    2021
  • 资助金额:
    $ 116.41万
  • 项目类别:
Mentorship of Junior Investigators on HEAL-SKOAP
HEAL-SKOAP 初级研究员的指导
  • 批准号:
    10426755
  • 财政年份:
    2021
  • 资助金额:
    $ 116.41万
  • 项目类别:
A sequenced-strategy for improving outcomes in patients with knee osteoarthritis pain
改善膝骨关节炎疼痛患者预后的序贯策略
  • 批准号:
    10352674
  • 财政年份:
    2019
  • 资助金额:
    $ 116.41万
  • 项目类别:
Increasing Participant Diversity in a 'Sequenced-Strategy to Improve Outcomes in people with Knee Osteoarthritis Pain (SKOAP)
增加“改善膝骨关节炎疼痛患者预后的顺序策略”(SKOAP) 的参与者多样性
  • 批准号:
    10400316
  • 财政年份:
    2019
  • 资助金额:
    $ 116.41万
  • 项目类别:
A sequenced-strategy for improving outcomes in patients with knee osteoarthritis pain
改善膝骨关节炎疼痛患者预后的序贯策略
  • 批准号:
    10271400
  • 财政年份:
    2019
  • 资助金额:
    $ 116.41万
  • 项目类别:
A sequenced-strategy for improving outcomes in patients with knee osteoarthritis pain
改善膝骨关节炎疼痛患者预后的序贯策略
  • 批准号:
    10258492
  • 财政年份:
    2019
  • 资助金额:
    $ 116.41万
  • 项目类别:
A sequenced-strategy for improving outcomes in patients with knee osteoarthritis pain
改善膝骨关节炎疼痛患者预后的序贯策略
  • 批准号:
    10917533
  • 财政年份:
    2019
  • 资助金额:
    $ 116.41万
  • 项目类别:
Opioid and cannabinoid combinations in laboratory and clinical pain
阿片类药物和大麻素组合在实验室和临床疼痛中的应用
  • 批准号:
    9479123
  • 财政年份:
    2017
  • 资助金额:
    $ 116.41万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 116.41万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 116.41万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 116.41万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 116.41万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 116.41万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 116.41万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 116.41万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 116.41万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 116.41万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 116.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了